"心脏糖化物"是什么?过去,现在和未来?
Julia Fender1, Johanna Klöcker1, Valérie Boivin-Jahns1
1Institute of Pharmacology and Toxicology, University of Würzburg, Versbacher Straße 9, 97078, Würzburg, Germany.
Naunyn-Schmiedeberg's archives of pharmacology
|July 15, 2024
概括
数字糖化物或心脏糖化物抑制Na+/K+-ATPase,用于心力衰竭和心房动. 这篇综述涵盖了它们的历史,研究和辩论的利弊.
科学领域:
- 药理学 药理学是指药理学的学科.
- 心脏病学 心脏病学
- 医学史 医学史 医学史
背景情况:
- 数字糖化物,也称为心脏糖化物,是已确定的Na+/K+-ATPase抑制剂.
- 这些药物在治疗心力衰竭和心房动方面有着悠久的历史.
- 尽管它们的使用,但它们具有狭窄的治疗范围和关于它们的指示的持续辩论.
研究的目的:
- 为了回顾数字糖的历史背景.
- 总结基础和临床研究中的关键发现.
- 讨论这些心脏糖化物被忽视的优点和缺点.
主要方法:
- 历史数据的文献评论. 历史数据的文献评论.
- 综合了基础科学研究中的发现.
- 对临床试验结果和患者数据的分析.
主要成果:
- 详细的数字糖化物使用的历史进展.
- 基本作用机制和临床效果的总结.
- 识别和讨论有益和有害的方面,包括安全概况.
结论:
- 心脏糖化物仍然是具有复杂的益处风险概况的相关治疗剂.
- 进一步的研究和仔细的患者选择对于优化它们的使用至关重要.
- 了解它们全方位的优缺点对于现代临床实践至关重要.
相关概念视频
Heart Failure Drugs: Inotropic Agents
564
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
564
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
964
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
964
Adrenergic Antagonists: ɑ and β-Receptor Blockers
430
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
430
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
733
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
733
Antianginal Drugs: Nitrates and β-Blockers
571
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
571
Heart Failure Drugs: β-Blockers
336
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336


